Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CACNA1H 8912 BEPRIDIL HYDROCHLORIDE CHEMBL1200382 blocker ChemblInteractions
CACNA1H 8912 MIBEFRADIL DIHYDROCHLORIDE CHEMBL1534525 blocker ChemblInteractions
CACNA1H 8912 FELODIPINE CHEMBL1480 inhibitor DrugBank 18974361, 1281221
CACNA1H 8912 PARAMETHADIONE CHEMBL1100 blocker ChemblInteractions
CACNA1H 8912 CINNARIZINE CHEMBL43064 inhibitor DrugBank 1281221, 3530295
CACNA1H 8912 BEPRIDIL CHEMBL1008 inhibitor DrugBank 7565636, 1281221
CACNA1H 8912 TRIMETHADIONE CHEMBL695 blocker ChemblInteractions
CACNA1H 8912 CELECOXIB CHEMBL118 PharmGKB
CACNA1H 8912 NITRENDIPINE CHEMBL475534 inhibitor DrugBank 18974361
CACNA1H 8912 FLUNARIZINE CHEMBL30008 inhibitor TdgClinicalTrial, TEND, DrugBank 11752352, 17139284, 17016423, 19582593, 11784784
CACNA1H 8912 PHENSUXIMIDE CHEMBL797 blocker ChemblInteractions
CACNA1H 8912 IMAGABALIN CHEMBL2103836 modulator ChemblInteractions
CACNA1H 8912 ETHOSUXIMIDE CHEMBL696 blocker ChemblInteractions
CACNA1H 8912 ATAGABALIN CHEMBL593430 modulator ChemblInteractions
CACNA1H 8912 PREGABALIN CHEMBL1059 modulator ChemblInteractions
CACNA1H 8912 GABAPENTIN ENACARBIL CHEMBL1628502 modulator ChemblInteractions
CACNA1H 8912 ISRADIPINE CHEMBL1648 inhibitor DrugBank 18974361, 1281221
CACNA1H 8912 ZONISAMIDE CHEMBL750 inhibitor TdgClinicalTrial, DrugBank 19557119, 14965331, 20025128, 18433351, 20001433, 14704463, 20502722, 15511691, 17762320, 19948168
CACNA1H 8912 MIBEFRADIL CHEMBL45816 inhibitor DrugBank 9375939, 14993472, 9670923, 15562257, 15498818, 17190903, 9481612, 16899990
CACNA1H 8912 GABAPENTIN CHEMBL940 modulator ChemblInteractions
CACNA1H 8912 METHSUXIMIDE CHEMBL697 blocker ChemblInteractions
CACNA1H 8912 NIFEDIPINE CHEMBL193 inhibitor DrugBank 16899990

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CACNA1H rs2753326 A lamotrigine efficacy yes as measured by minor allele frequency in not–seizure‐free vs seizure-free children. Authors do not specify which allele is minor allele but state "Two synonymous CACNA1H variants, located essentially next to each other (rs2753326 and rs2753325), were associated with greater seizure freedom in the lamotrigine group. Both have global minor allele frequency reported as 0.29 compared to 0.36 in the lamotrigine cohort." This does not seem to match with frequencies in Table 2. Assumed minor allele as same as dbSNP which was A and major allele as G. Allele A is associated with increased clinical benefit to lamotrigine in children with Epilepsy as compared to allele G. 28165634 1451134105
CACNA1H rs2753325 A lamotrigine efficacy yes as measured by minor allele frequency in not–seizure‐free vs seizure-free children. Authors do not specify which allele is minor allele but state "Two synonymous CACNA1H variants, located essentially next to each other (rs2753326 and rs2753325), were associated with greater seizure freedom in the lamotrigine group. Both have global minor allele frequency reported as 0.29 compared to 0.36 in the lamotrigine cohort." This does not seem to match with frequencies in Table 2. Assumed minor allele as same as dbSNP which was A and major allele as G. Allele A is associated with increased clinical benefit to lamotrigine in children with Epilepsy as compared to allele G. 28165634 1451134380
CACNA1H rs61734410 T ethosuximide efficacy yes as measured by minor allele (T) frequency in not–seizure‐free vs seizure-free children. Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C. 28165634 1451134040
CACNA1H rs1054645 A antiepileptics efficacy no Alleles given as T and C. No SNPS analyzed alone were significantly associated with drug response, but the TAGAA haplotype in CACNA1A was found to be a significant predictor of anti epileptic drug resistance (p=0.00059). Odds ratio 2.129 (95% CI: 1.373-3.299). The most common drugs were valproic acid (42.7%), oxcarbazepine (27.7%), lamotrigdine (25.4%), phenyoinum (14.8%), levetiracetam (13.3%), phenobarbital (8.3%), and topiramate (7.9%). Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G. 26216687 1447986278
CACNA1H rs3751664 C antiepileptics efficacy no No SNPS analyzed alone were significantly associated with drug response, but the TAGAA haplotype in CACNA1A was found to be a significant predictor of anti epileptic drug resistance (p=0.00059). Odds ratio 2.129 (95% CI: 1.373-3.299). The most common drugs were valproic acid (42.7%), oxcarbazepine (27.7%), lamotrigdine (25.4%), phenyoinum (14.8%), levetiracetam (13.3%), phenobarbital (8.3%), and topiramate (7.9%). Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T. 26216687 1447986304
CACNA1H rs3794619 T antiepileptics efficacy no No SNPS analyzed alone were significantly associated with drug response, but the TAGAA haplotype in CACNA1A was found to be a significant predictor of anti epileptic drug resistance (p=0.00059). Odds ratio 2.129 (95% CI: 1.373-3.299). The most common drugs were valproic acid (42.7%), oxcarbazepine (27.7%), lamotrigdine (25.4%), phenyoinum (14.8%), levetiracetam (13.3%), phenobarbital (8.3%), and topiramate (7.9%). Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C. 26216687 1447986286
CACNA1H rs7191246 C antiepileptics efficacy no No SNPS analyzed alone were significantly associated with drug response, but the TAGAA haplotype in CACNA1A was found to be a significant predictor of anti epileptic drug resistance (p=0.00059). Odds ratio 2.129 (95% CI: 1.373-3.299). The most common drugs were valproic acid (42.7%), oxcarbazepine (27.7%), lamotrigdine (25.4%), phenyoinum (14.8%), levetiracetam (13.3%), phenobarbital (8.3%), and topiramate (7.9%). Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G. 26216687 1447986292